药物设计-基于结构和配体的方法 1741条(本栏目收费,不能显示细节,电话15274084725)
visualization clarity of, 35 35
future prospects for, 38–39 39
leadlike properties in, 31–32 32
protein kinases in, 37 37
SAR optimization in, 35–37 37
binding sites in, 36, 38 38
fragment choice in, 36 36
fragment engineering in, 36 36
ligand efficiency in, 36 36
in target enabling, 32 32
SMERGE program for, 37 37
with complementary biophysical 0
target enabling in, 32, 33–34 34
modular robotics in, 33–34 34
SAR optimization in, 32 32
x-ray screening in, 35 35
siRNA. See small interfering RNA 0
small group scans, 10–11 11
small interfering RNA (siRNA), 1 1
SMERGE program. See Scaffold MErging via 0
Recursive Graph Exploration 0